Product Pipeline
Our innovative approach to drug development has resulted in a pipeline of drug candidates that offer novel, differentiated treatments for a range of chronic diseases, including autoimmune and central nervous system (CNS) diseases.
An investigational JAK inhibitor designed to target the immunological basis of alopecia areata. CTP-543 is an oral inhibitor of Janus kinases JAK1 and JAK2. Learn more >
An investigational deuterium-modified form of d-serine for the adjunctive treatment of schizophrenia. CTP-692 is being investigated as a treatment for positive and negative symptoms as well as cognitive dysfunction to more broadly treat the symptoms of schizophrenia than has been previously possible. Learn more >
Warning: Illegal string offset 'avp_786_text' in /home/concertp/public_html/wp-content/themes/Orchestra/page-pipeline.php on line 203
Strategic Collaborations
Concert’s platform has driven product development programs and resulted in novel drugs that are being developed under strategic collaborations.
